MP51-20 MOLECULAR REPROGRAMMING AND REWIRING OF PROSTATE CANCER CELLS AFTER ENZALUTAMIDE EXPOSURE

INTRODUCTION AND OBJECTIVE:Enzalutamide (ENZU), an androgen receptor (AR) inhibitor, has demonstrated clinical benefit in patients with advance-stage prostate cancer. However, it only provides a tr...